Eastern Illinois University

The Keep
Masters Theses

Student Theses & Publications

2000

Relationship Between Protective Effects of
Estrogen, ApoE and Alzheimer's Disease
Sara M. Ludwig
Eastern Illinois University

This research is a product of the graduate program in Biological Sciences at Eastern Illinois University. Find
out more about the program.

Recommended Citation
Ludwig, Sara M., "Relationship Between Protective Effects of Estrogen, ApoE and Alzheimer's Disease" (2000). Masters Theses. 1476.
https://thekeep.eiu.edu/theses/1476

This is brought to you for free and open access by the Student Theses & Publications at The Keep. It has been accepted for inclusion in Masters Theses
by an authorized administrator of The Keep. For more information, please contact tabruns@eiu.edu.

THESIS/FIELD EXPERIENCE PAPER
REPRODUCTION CERTIFICATE

TO:

Graduate Degree Candidates (who have written formal theses)

SUBJECT:

Permission to Reproduce Theses

The University Library is receiving a number of request from other institutions asking
permission to reproduce dissertations for inclusion in their library holdings. Although no
copyright laws are involved, we feel that professional courtesy demands that
permission be obtained from the author before we allow these to be copied.
PLEASE SIGN ONE OF THE FOLLOWING STATEMENTS:
Booth Library of Eastern Illinois University has my permission to lend my thesis to a
reputable college or university for the purpose of copying it for inclusion in that
institution's library or research holdings.

K/J/oo
I

Date

I respectfully request Booth Library of Eastern Illinois University NOT allow my thesis to
be reproduced because:

Author's Signature

lhes1S4 form

Date

Relationship Between Protective Effects of Estrogen. ApoE
and Alzheimer ' s Disease
(TITLE)

BY

Sara M. Ludwig , B. A.

THESIS
SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
FOR THE DEGREE OF

Master of Science
IN THE GRADUATE SCHOOL, EASTERN ILLINOIS UNIVERSITY
CHARLESTON, ILLINOIS

2000
YEAR

I HEREBY RECOMMEND THAT THIS THESIS BE ACCEPTED AS FULFILLING
THIS PART OF THE GRADUATE DEGREE CITED ABOVE

DATE

~/ 1/00
DATE

Relationship Between Protective Effects of Estrogen,
ApoE and Al zheimer's Disease

A Thesis
Presented To The
Faculty Of
Oepartn1ent Of Biological Sciences
At

Eastern Illinois Un iversity

In Partial Fu lfillment
Of The Req u irem ents For The Degree
Master of Science
In
Biological Sciences

By
Sara M. Ludwig, B.A.
Summer semester 2000

Acknowledgements

Completion of my research project and my thesis has been both a difficult and
rewarding experience. I would like to say a very special thank you to my mentor, Dr.
Britto P. Nathan. Without him, I would not have been able to accomplish any of this
research. I would like to thank him for his support, encouragement, guidance, and
assistance throughout my research. I would also like to thank my committee members,
Dr. Kipp Kruse and Dr. Gene Wong for their assistance and support. I would like to say
a big thank you to Dr. Kipp Kruse for al l his help on my statistical analysis and for his
encouragement. 1 would like to say a very special thank you to my parents who always
support and encourage me no matter what. Without them, I would never have made it
this far. Finally, I would like to thank my friends and colleagues at the lab who have
supported me and have shared both good and bad times in the ever-frustrating endeavor
to advance our understanding in the world of science. I would like to thank all of them
for making the lab a bearable and eve n happy place to work. I hope that this research
will prove usefu l in the struggle to unravel the mechanisms leading to Alzheimer's
Disease.

iii

TABLE OF CONTENTS
Page
Acknowledgements

Ill

List of Figures

v

Abstract
Introduction

3

Material and Methods

12

Results

18

Discussion

29

Literature Cited

33

List of Figures
Figure

Page

1. Western im munoblot for apoE two weeks post-lesion

21

2. Quantification of apoE in the olfactory bulb two weeks post-lesion

22

3. Western immunoblot for GFAP two weeks post-lesion

23

4. Quantification ofGFA P in the olfactory bulb two weeks post-lesion

24

5. Western immunoblot for OMP two weeks post-lesion

25

6. Quantification of OMP in the olfactory bulb two weeks post-lesion

26

7. Western immunoblot for synaptophysin two weeks post-lesion

27

8. Quantification of synaptophysin in the olfactory bulb two weeks post-lesion

28

Abstract

Alzheimer's disease (AD) is a neurodegerative disorder characterized by
progressive memory loss and loss of cognitive function. The pathogenesis and
progression of AD is poorly understood. Recently, several risk factors have been
determined, however, how these risk facto rs function to induce AD onset has yet to be
elucidated.
Apolipoprotein E genotype has been clearly demonstrated to be a ri sk factor for
AD. The apoE2 and apoE3 isoforms appea r to be protective against AD, whereas the
apoE4 isoform has been implicated in the development of AD. The apoE4 allele works
in a dosage-dependent fashion ; that is, the greater the expression of apoE4, the earli er the
onset of AD and the quicker the progression. ApoE has been clearly shown to play a
central role in nerve repair and regeneration in the central nervous system (CNS) and
peripheral nervous system (PNS ), however, its precise functions in these repair processes
remain uncl ear.
Recently, it has been acknowledged that significantly more females are affi icted
with AD than males; this has been suggested to be due to estrogen loss at menopause.
Several studies have shown that women receiving estrogen replacement therapy (ERT)
have a reduced risk of developing AD, and if they do develop AD, the progression is
slower and the age of onset is later. lt is thought that estrogen somehow modulates apoE
levels and/or function in the CNS, however, estrogen's role in the CNS is poorly
understood.
The major objective of this study was to determine the effects of estrogen on
nerve regeneration in the olfacto1y system of mice. In order to study the effects of

estrogen on nerve regeneration, mice were ovariectomized (OVX) and divided into four
treatment groups. Estrogen or placebo pellets were implanted in the nape of the animals'
necks and mice were then irrigated with either Triton (lesioned) or saline (control).
Western im munoblotting techniques were then used to quantitate specific marker proteins
in the olfactory bulbs. These biochemical markers shed light on regeneration events
occurring within the system.
Results indicated that estrogen does indeed play a significant role in CNS repair.
Lesioning was shown to recruit glial cells to the site of injury (shown by blotting for
GF AP). These gl ial cells then up-regulate apoE in order to faci litate neuronal repair, as

shown by apoE immunoblots. Estrogen treated lesioned animals showed significantly
more nerve repair (shown by olfactory marker protein or OMP blots) than in the lesioned
mice receiving no estrogen. Finally, blots for synaptophysin indicated that more
synapses were formed in the estrogen treated lesioned group as compared to the lesioned
group not receiving estrogen. In all cases, there were no significant differences between
the two non-lesioned groups.
These results strongly suppo11 the notion that estrogen facilitates apoE function in
nerve repair in the CNS . Further studies at the molecular level are required to understand
how estrogen and apoE work in concert to facilitate nerve repair.
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Introduction
Apolipoprotein E (apoE) is a 34-kDa-protein component of very low-density
lipoproteins (VLDL), chylomicrons, chylomicron remnants, and high-density lipoproteins
(HDL) (Mahley, 1988). In its mature form in plasma and cerebrospinal fluid (CSF),
apoE is 299 amino acids in length (Mahley, 1988). ApoE plays a central role in the
regulation of lipoprotein metabolism and in the control of lipid transport and lipid
redistribution among target tissues and cells (Weisgraber, 1994). Lipid transport and
redistribution is regulated by apoE via interaction with lipoprotein receptors (Mahley,
1988). Receptor-lipoprotein binding initiates cellular uptake and degradation of the
lipoproteins. The lipid becomes available for utilization in the regulation of intracellular
cholesterol metabolism. ApoE, therefore, serves as a ligand for the receptor-mediated
clearance of lipoproteins from the plasma (Rall et al., 1982).
The apoE gene is 3597 nucleotides in length and contains four exons (Mahley,
1988). ApoE is encoded by an 1163-nucleotide mRNA (Mahley, 1988). In humans,
there are three major isoforms of apoE, designated as apoE2, apoE3, and apoE4, that are
products of the three alleles (designated E2, c3, and c4) located at a single gene locus on
the long proximal arm of chromosome 19 (Mahley, 1988). The molecular basis of this
polymorphism of the apoE gene results from cysteine-arginine interchanges at two
positions in the apoE protein (Weisgraber, 1994). These single amino acid substitutions
are found at residues 11 2 and 158 (Rall et al., 1982). The most common isoform, apoE3,
contains cysteine at residue 112 and arginine at position 158. ApoE2 has cysteine at both
positions and apoE4 contains arginine at both positions (Weisgraber, 1994).
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Many organs synthesize apoE; the largest quantity is made in the liver, followed
by the brain (Boyles et al ., 1985). In these organs, a wide variety of cell types are
capable of producing apoE, which includes macrophages (Mahley, 1988), astrocytes
(Pitas et al., 1987) and oligodendrocytes (Stoll et al., 1989). In addition to its function in
lipid metabolism as previously mentioned, apoE has also been implicated in a wide
variety of other physiological processes throughout the body. ApoE may have a
structural role in a number of lipoprotein particles as well as regulating their metabolism
(Wisniewski and Frangione, 1992). ApoE is also thought to function in
immunoregulation (Cuthbert and Lipsky, 1984), nerve repair and regeneration in both the
central nervous system (CNS) and the peripheral nervous system (PNS), nerve growth
(Ignatius et al., 1986; Ignatius et al., 1987; Snipes et al., 1986; Boyles et al. 1989;
Handelmann et al. 1992), modulation of intracellular cholesterol utilization (Reyland et
al., 1991), steroidogenesis in adrenal cells (Reyland and Williams, 1991 ), and as an
activator or modulator of hepatic lipase (Ehnholm et al., 1984; Landis et al., 1987; Thurin
et al., 1991, 1992).

ApoE is thought to participate in the mobilization and redistribution

of lipids during normal development of the nervous system (Pitas et al., 1987) and in the
regeneration of peripheral nerves after injury (Boyles et al., 1989).
The exact function of apoE in the nervous system is poorly understood, but the
mechanisms in which it is involved are of pa11icular interest. ApoE levels increase in
response to injury in both the CNS and the PNS (Ignatius et al., 1986). In rats, the
synthesis of apoE increases by 250- to 3 50-fold within three weeks following peripheral
nerve injury (Snipes et al ., 1986; Boyles et al., 1989). It has also been reported that
macrophages synthesize and release apoE following peripheral lesion which accumulates
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to 5% of total extracellular protein (Skene and Shooter, 1983). It has been suggested that
this accumulation of apoE is to scave nge cholesterol from the degenerating myelin and
recycle it to the growth cones of sprouting axons by LDL-receptor-mediated endocytosis
for membrane biosynthesis (Mahley, 1988; Goodrum et al., 1995; Poirier et al., 1993).
Based on these observations, it has been proposed that apoE is involved in
neurodegenerative processes by isoform-specific effects on neurite outgrowth and
cytoskeletal stability (Mahley et al., 1995; Weisgraber and Mahley, 1996). In vitro
studies have shown that addition of apoE3 to dorsal root ganglion neurons in culture
stimulated neurite outgrowth whereas apoE4 decreased neurite extension (Nathan et al.,
1994). These data imply that apoE is important for peripheral nerve regeneration
(Mahley, 1988). The data from apoE knock out (apoE KO) mice, however, does not
support this hypothesis. Regenerating nerves in both control mice and apoE KO mice
were morphologically identical at two and four weeks following sciatic nerve crush
(Popke et al., 1993; Goodrum, 1995 ). This suggests that other apolipoproteins in the
PNS may substitute for apoE when it is absent. Hence, the specific role of apoE and its
importance in the PNS remains unclear.
The precise function and mechanism of action of apoE is even less clear in the
central nervous system. ApoE is the principle apolipoprotein in the brain and
cerebrospinal fluid (CSF). The majority of apoE in the CNS is synthesized and secreted
primarily by glial cells, and by microglia to a lesser extent (Pitas et al., 1987; Pitas et al.,
, 1987; Borghini et al., 1995; Boyles et al. , 1985; Naikai et al., 1996). ApoE is the only
apolipoprotein in the CNS that is able to interact with lipoprotein receptors (Pitas et al.,
1987; Borghini et al., 1995). Cells within the brain express four receptors for apoE-
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containing lipoproteins: the low density lipoprotein (LDL) receptor, the LDL receptorrelated protein (LRP), the very low density lipoprotein (YLDL) receptor, and the
glycoprotei n (gp) 330. The LDL receptor and the LRP are expressed by neurons (Pitas et
al., 1987; Boyles et al., 1985). It has been shown that the VLDL receptor in the CNS is
expressed in some human neurons, whereas gp330 is expressed by brain ependymal cells
(Willnow et al., 1992; Sakai et al., 1994; Kim et al., 1996; Kounnas et al., 1994). It has
been reported that human apoE-containing lipoproteins bind to fibroblast LDL receptors
and that the LDL receptor and the LRP mediate the binding and internalization of apoEcontaining li poproteins in cultured neurons (Bellosta et al., 1995). These studies provide
evidence that the apoE and apoE-containing lipoproteins are present within the brain
where they can interact with neurons and that li poprotein transport by apoE is important
for normal fu nctioning of adult neurons.
Increased apoE immunoreactivity is present in the brains of patients with such
neuro logical disorders as Alzheimer' s disease (AD), Down' s syndrome, and CreutzfeldJacob disease (Namba et al., 1991 ). It has been demonstrated that expression of apoE
increases following optic nerve injury, but absolute levels of apoE do not increase
(Ignatius et al., 1986). ApoE mRNA is increased in the brains of AD patients (Diedrich
et al., 1991) and in response to injury in both the PNS (Boyles et al., 1989) and CNS
(Sni pes et al., 1986).
It ha_s been shown that addition of apoE3 to a culture stimulates neurite outgrowth

in transformed murine neuroblastoma (Neuro-2a) cells, whereas apoE4 inhibits neurite
extension (Bellosta et al., 1995). Recent studies show that apoE knock out (apoE KO)
mice display significant synaptic loss and disru ption of the dendritic cytoskel eton with
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age and a reduced recovery following perforant pathway lesioning (Masliah et al., 1995~
Masliah et al., 1996; Masliah et al., 1997). Synaptophysin (a marker presynaptic
terminals) and microtubule-associated protein (MAP-2, a dendritic marker) levels in the
hippocampus and neoconex of apoE KO mice were shown to decrease as compared to
age-matched control mice. However, other studies have not observed any significant
morphological deficits in apoE KO mice (Anderson et al., 1998). The reasons underlying
these inconsistencies are not clear, but differences in the strain and age of both the apoE
KO and the control mice used may have contributed to the inconsistent results observed.

In contrast to the morphological studies, behavioral studies have consistently
shown that apoE KO animals exhibit spatial learning deficits (Masliah et al., 1996;
Gordon et al., 1995; Gordon et al., 1996). Infusion of recombinant apoE into the lateral
ventricles of apoE KO mice reversed behavioral and morphological anomalies (Masliah
et al., 1996). Other studies involving apoE KO mice have suggested that apoE may be
involved in protecting the brain against acute injury (Chen et al., 1997). These results
provide convincing evidence that apoE plays a critical role in neuroprotection,
preservation, and plasticity within the CNS.
Studies of apoE within the CNS have shed some light on neurodegenerative
disorders, especially Alzheimer' s disease (AD). ApoE genotype has been shown to be a
major risk factor for AD. ApoE immunoreactivity is associated with neurofibri llary
tangles and neuritic plaques, the characteristic pathological structures present in the
brains of AD patients (Namba et al., 1991 ; Wisniewski and Frangione, 1992; Schmechel
et al., 1993; Strittmatter et al., 1993 ). The neuritic plaques are, for the most part,
extracellular and constitute classical amyloid deposits and often a neuritic component.
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The major protein present in these plaques is the amyloid beta peptide (Ab), which is
formed by cleavage of the amyloid precursor protein (APP) (Haass and Selkoe, 1993). It
has been demonstrated that apoE is associated with Ab deposits in neuritic plaques and in
the angiopathy of cerebral vessels (Strittmatter et al., l 993). Unlike neuritic plaques,
neurofibrillary tangles are intracellular and contain structures known as paired helical
filaments (Goedert et al., 1992). The role of these plaques and tangles in the progression
of AD is not yet clear.
T here are three forms of AD: early-onset fam ilial, late-onset familial, and lateonset sporadic. Early-onset AD represents approximately 5% of patients, whereas lateonset AD accounts for a majority of AD cases. Recent studies have indicated a
relationship between the apoE4 allele and late-onset familial AD (Strittmatter et al.,
1993) as well as late-onset sporadic AD (Tsai et al., 1994). It has been demonstrated that
the risk of early-onset AD and disease progression increase is related to the number of
apoE4 alleles in a dose-dependent fashion (Tsai et al., 1994; Corder et al., 1993). The
frequency of the apoE4 allele has been shown to be greatly over-represented in late-onset
fami lial AD patients (representing 52% of the subjects) versus controls (16%), and the
risk of AD in individuals homozygous for the apoE4 allele is over five times that of
homozygous apoE3 individuals (Corder et al., 1993).
Another recent study suggests that the apoE4 allele may also be involved with age
of onset in Parkinson's disease. This evidence strongly suggests that there is a definite
correlation between apoE polymorphism and the development of neurodegenerative
disorder (Nisar, 1999). The mechanism behind the pathogenesis of these disorders and
the exact effects of apoE on CNS neurons remain unclear. One possible mechanism of

apoE in AD may involve neuronal plasticity, based on previous studies which suggest
that apoE may play a crucial role in nerve regeneration.

In addition to apoE genotype, it seems that estrogen plays an important protective
role in the development of AD . The risk of AD and related dementia for women who
used estrogen replacement therapy (ERT) was reduced by about one third below that of
women who had never used ERT (Paganini-Hill and Henderson, 1996). Recent studies
have suggested that estrogen's protective effects are through its action as a trophic factor
for cholinergic neurons, a modulator for the expression of apoE in the brain, an
antioxidant compound decreasing the neuronal damage caused by oxidative stress, and a
promoter of the physiological nonamyloidogenic processing of the APP, decreasing the
production of the Ab protein (Inestrosa et al., 1998).
It has been demonstrated that ERT increases cerebral and cerebellar blood flows
in postmenopausal women (Ohkura et al., 1995). Cerebral blood flow values are shown
to be hi gher in females than in males until the age of 50 (Davis et al., 1983) or 60 (Shaw
et al., 1984). Furthermore, ERT improves cognitive functions and increases regional
cerebral blood flow in female patients with dementia of the Alzheimer type (Ohkura et
al., 1994).
Estrogen receptors have been reported in astrogl ia, sheathing glia, and microglia
(Azcoitia et al., 1999; Mor et al., 1999). This suggests that estrogen may be able to
"activate" gli al cells (Strubl e, personal communication). However, a simple activation or
inactivation of glial cells by estrogen has not been reported in vivo. One study
demonstrated that estrogen effects on glia represented an interaction between neurons and
glial cells (Stone et al. , 1998). Estrogen appears to regulate apoE gene expression in an
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organ specific manner (Srivastava et al., 1996). A 1.4-fold increase in apoE mRNA in
the brain followed after five days of I 7j3-estradiol administration in mice (Struble,
personal communication). However, several other organs (includi ng the liver and
intestine) displayed no changes.
It has been clearly shown that estrogen replacement therapy (ERT) reduces the
risk of AD and also delays the age of clinical onset (Waring et al., 1999; Paganini-Hill,
1994). It has also been found that estrogen replacement in experimental animals
promotes recovery from neurological damage (Stone et al., I 998; Stone et al., 1997;
Toung et al., 1998), and that estrogen administration increases apoE and glial markers.
The exact mechanism by which estrogen facil itates nerve repair is still unknown.
Recent studies ha ve shown that ERT has no detectable effect on cognitive
functions in neurologically intact postmenopausal women. Parallel studies in mice,
evaluating the effects of long-term estrogen elevation, found only transient changes in the
synaptic density of olfactory neurons (Nathan, personal commu nication). These results
suggest that estrogen's effects on the CNS, in neurologically intact animals, are only
transitory.
Based on these previous studies I hypothesized that I) estrogen's main effect in
the CNS is to facilitate the repair process, and will only have a mild and transitory effect
in the absence of damage; and 2) estrogen faci litates repair by up-regulating apoE.
The major aim of this study is to determine the effects of estrogen on apoE level,
glial cells, and synaptic density in the olfactory bulb of control mice following olfactory
nerve lesioning. The olfactory system is selected as a model because lesioning techniques
may be used to amplify tissue repair processes that normally occur in this system.
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Western immunoblotting will be used to det ermine differences in apoE, synaptophysin,
GFAP, and OMP levels in lesioned and non-lesioned mice. All mice will be
ovariectomized (OYS) in order to study the effects of estrogen and the absence of
estrogen on these marker proteins.

ll

Materials and Methods
Animals
Breeding pairs of C57BL6J mi ce were purchased from Jackson Laboratories (Bar
Harbor, ME). Two to three month old female mice were used.

Treatment Groups
Animals were randomly divided into 4 treatment groups (n = 5-8 for each group)
as follows:
ovariectomized /Estrogen pellet/Triton irrigated (lesioned)
ovariectomized /Placebo pellet /Triton irrigated (lesioned)
ovariectomized /Estrogen pellet /Saline irrigated (control)
ovariectomized /Placebo pellet /Sa line irrigated (control)

Surgery
Animals were either ovariectomized (OVX) or sham operated, depending on the
treatment group. All animals were anesthetized with an intraperitoneal injection of
sodium pentobarbital (80 mg/kg). The incision site was shaved and an aseptic bilateral
dorsal incision made just under the rib cage. The fallopian tube was clamped just below
the ovary and the ovary was then completely removed. The muscle layer was sewn with
silk ligatures and the skin was closed with autoclips. The same procedure was followed
on the opposite side.

I?

Pellet Implantation
A

17-~

estradiol pellet (SE-121, Innovative Research of America, Sarasota,

Florida) or a placebo pellet (SC-1 11 , Innovative Research of America, Sarasota Florida)
was implanted into each animal in the appropriate treatment groups at the time of
surgery. The pellet was placed just under the skin at the back of the animals' necks with
a 12 Gauge trochar.

Nasal Irrigation
Three days after surgery and pellet implantation, mice were irrigated with 0.9%
saline (SL) or lesioned with 0.7% Triton X-100 (TX), as previously described
(Verhaagen et al ., 1990) depending on treatment group. Briefly, a 25 gauge needle 10
mm in length with a rounded tip, was inserted about 2 mm into one nostril, and l 00 µL of
0.7% Triton X-100 (B P1 51-500, Fi sher) in 0 9% saline or 0.9% saline (control) was
squirted into a nostril of unanesthetized mice (Verhaagen et al., 1990). The excess
solution was drained from the nasal passage by gently shaking the mice. This technique
results in complete bilateral nerve lesion (Verhaagen et al., 1990).

Sacrifice
Mice were sacrificed 17 days after su rgery and pellet implantation. Mice were
anesthetized by an intraperitoneal injection of sodium pentobarbital (80mg/kg). After the
animals were deeply anesthetized, a needle was inserted transcardially and the animals
were thoroughly perfused with phosphate buffered saline (pH 7 4). The olfactory bulbs
were dissected and processed as described below.

13

Tissue Preparation
The olfactory bulbs were homoge ni zed in ice cold TMN buffer (25 mM Tris-HCI
[pH 7.6] 3 mM MgCb, 100 mM NaCl, 1 mM phenylmethylsulfonyl fluoride) (Xu et al. ,
1996). The homogenate was lysed by adding 1% Triton X-100, 0.5% deoxycholate, and
0.2% SOS on ice for 5 min (Xu et al ., 1998). The homogenate was then centrifuged for 2
min in a microcentrifuge (g

= 13,000) (Xu et al.,

1998). The supernatant was saved for

protein assay and western immunoblot analysis.

Protein Assay
Protein assay was performed by Lowry protein assay method modified by
Peterson (Peterson, 1977). Briefl y, 5

~d

of homogenized olfactory bulb sample was

diluted to 50 µl with double distilled water, and I 0 µI of diluted samples (in triplicates)
were protein assayed . The volume of each of the JO µl triplicates was brought to 400 µl
w ith double distilled water. Four hundred microliters of Lowry Reagent A (equal volume
of dH 20 , 0.8N NaOH, copper ta11arate carbonate, and 10% SOS) was added and the
samples vortexed. Following 10 min of incubation at room temperature, 200 µl of Lowry
Reagent B (I part Folin-Ciocalteu ' s phenol reagent [F-9252, Sigma, St. Louis, MO] and
5 parts of dH20 was added, vorte:xed, and incubated fo r 50 min at room temperature for
color development. Absorbance was recorded at 750 nm using a spectrophotometer.
Bovine albumin serum (A-75 11 , Sigma, St. Louis, MO) was used as a standard sample
for the protein assay.
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SDS - Polyacrylamide Gel Electrophoresis
Proteins in the olfactory bulb were resolved by SOS-PAGE as previously
described (Bellosta et al., 1995). Briefly, 20

~tg

of olfactory bulb protein was mixed with

an equal volume of 2X Lammeli sample buffer (6.25 ml 4X Tris/SDS [pH 6.8], 5 ml
glycerol, lg SDS, 0.5 ml 2-mercaptoethanol, bromophenol, 13.25 ml dH20) . Samples
were boiled for 5 min and then centrifuged at 14,000 g for 5 min. The gel cassettes were
inserted into the buffer tank of an EC 120 Mini gel vertical system (E-C Apparatus
Corporation, St. Petersburg, FL) containing IX running buffer, pH 8.3 [250 ml of 5X
running buffer (15 g Tris-base, 72 g glycine, 5 g SOS, 750 ml dH20].
The samples and 5 µI of kaleidoscope prestained standards (161-0324, Bio-Rad
Laboratories, Hercules, CA) were electrophoresed through a pre-cast 4-20% gradient gel
(Fisher, FB3435). Samples were electrophoresed at 80 volts until separation began, and
then at 140 volts until the dye front reached the bottom of the gel.

Protein Transfer
Following electrophoresis, the gel was placed in transfer buffer (3 .03 g Tris-base,
14.4 g glycine, 200 ml methanol , 800 ml dH 20) on a shaker. The transfer membrane
(Immobilon-P IPVHOOO I 0, Millipore, Bedford, MA) was soaked in methanol for 5 sec
and then washed in dH 20 for 5 min. The gel was placed on presoaked filter paper in the
holder and the transfer membrane was placed on top of the gel. Using a trans-blot transfer
cell (170-3930, Bio-Rad), proteins from the gel were transferred onto the membrane by
passing I 00 volts for an hour.
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Western Immunobloting

Apo£
ApoE was quantified as previously described (Xu et al., 1996). Briefly, the blots
were incubated in polyclonal goat antiserum against human apoE (178479, Calbiochem,
San Diego, CA) (1 :5,000 dilution in T-TBS (pH 7.6] 0 . 1M Tris, 0.15M NaCl, 0.1 %
Tween-20) for 30 min on a shaker at room temperature. The membrane was then washed
4 times (10 min each) in T-TBS. The blot was then incubated in the secondary antibody
solution (rabbit anti-goat IgG-HRP [AP I 06P, Chemicon, Temecula, CA] 1: 10,000
dilution) for 30 min on a shaker at room temperature. Blots were washed with T-TBS 5
times (10 min each) (Xu et al., 1996). lmmunoreactive bands were then visualized with
SuperSignal West Pico Chemiluminescent substrate (34080, Pierce, Rockford, IL) and
then exposed to BioMax film (Kodak).

GFAP
To quantitate GFAP, blots were incubated in mouse anti-GFAP (BYA60771,
Accurate Chemical & Scientific Corp, Westbury, NY) (I :2,000 dilution in TBST) for on
hour on an orbital shaker at room temperature. Blots were then washed 4 times (10 min
each) in TBST, pH 7.5 (20 mM Tris-HCI, 150 mM NaCl, 0.1 % Tween-20, 0.1 g BSA].
Blots were incubated in secondary antibody solution (goat anti-mouse lgG-HRP)
(AP124P, Chemicon, Temecula, CA) I : 1,000 dilution in TBST) on an oribital shaker for
one hour at room temperature. The blots were then washed 5 times (10 min each) in
TBST. Visualization of the bands was done using the same protocol as previously
described for apoE.
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OMP

The same protocol was used as above, except dilutions differ. Primary antibody
solution consists of goat anti-rat OMP (a generous gift from Dr. Frank Margolis, Univ. of
Mass) ( l : l 0,000 dilution in TBST). Secondary antibody solution is rabbit anti-goat IgGHRP (AP l 06P, Chem icon, Temecula, CA) (I :5,000 di lution in TBST).

Synaptophysin

The same protocol was used as above to quantitate synaptophysin. Primary
ant ibody solution consists of rabbit anti-human synaptophysin (AOO I 0, DAKO,
Carpinteria, CA) at I :2,000 dilution in TBST. The secondary antibody was goat antirabbit IgG-HRP (AP I32P, Chemicon, Temecula, CA) (l :1,000 dilution in TBST).

Quantitation/Data Analysis
All experiments were repeated at least three times to assure reproducibility of the results.
Bands were quantified by densitometry (Scion Image). As an internal control, the blots
also contained an olfactory bulb extract from unlesioned animals. A one-way analysis of
variance was used to compare treatment means. If a significant F value was found, a
Duncan's Multiple Range mean comparison test was used to differentiate significance
between and among means.
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Res ults

In this study, mice were ovariectomized (OVX) and either a I7j3-estradiol pellet or a
placebo pellet was implanted subcutaneously in the nape of the neck. Olfactory nerve lesioning
was performed by intranasal irrigation with Triton X-100 (TX) in saline three days after surgery
and pellet implantation. The animals were divided into fou r treatment groups: 1)
OVX/lesion/estrogen (TX+E2) (n=S-7), 2) OVX/lesion/placebo (TX+PL) (n=S-7), 3) OVX/no
lesion/estrogen (S L+E2) (n=S-7), and 4) OVX/no lesion/no estrogen (SL+PL) (n=S-7). Olfactory
bulbs were collected 14 days after lesioning. The expression of four marker proteins: apoE,
GFAP, OMP, and synaptophysin were examined using western immunoblotting.

Western immunoblotting or apoE revealed a significant increase in the amount of apoE in
mice that were treated with estrogen following lesioning of the olfactory nerve (Figure 1).
Quantification by densitometry confirmed this with apoE showi ng significantly higher levels of
apoE in the mice with olfactory nerve lesions and estrogen (Figure 2). There were no significant
differences in apoE levels in the other experimental groups.
Statistical analysis showed that Bulb levels of apoE in the four treatment groups were not
equal (Feat= 4.31, P = 0.017). ApoE in TX+E2 group were significantly higher than that in the
other three groups which were statistically indistinguishable from each other (P > 0.05).

IR

GFAP
Western immunoblotting ofGFAP demonstrated a significant increase in the
amount of GF AP in nerve-lesioned mice, independent of estrogen administration (Figure
3). Quantification by densitometry (Figure 4) confirmed this, showing significantly
higher levels ofGFAP both of the lesion ed groups. The other experimental groups
showed no significant differences in expression of GFAP.
Statistical analysis showed that GF AP levels differed among the four treatment
groups. Bulb GFAP levels inTX+E2 and TX+PL were significantly (Fcal

= 5.86, P =

0 .0067) higher than the SL+E2 and SL+P L groups. There were no significant differences
(P > 0.05) between TX+E2 and TX+ PL. Also, there were no significant differences (P >
0.05) between the SL+E2 and SL+PL groups.

Western immunoblotting revealed that OMP levels in the olfactory bulb of
TX+E2 were more than 2 times higher than the TX+ PL group, although none of the
treatment means differed significantly (F,.a1= 2 .03, P = 0.15). The OMP levels in the
TX+E2 group were about 40% of those in the SL+E2 and SL+PL groups. The
differences in OMP levels in the SL + E2 group and the SL+PL group were not significant.
These results are illustrated in Figure 5.
In sum, OMP expression is increased in the lesioned and estrogen replaced group
as compared to the unlesioned and estrogen replaced group (Figure 6), but this trend was
not statistically significant, due to variation within the treatment groups.

10

Synaptophysin
Western immunoblotting of sy naptophysin revealed a significant increase in the
amount of synaptophysin in the olfactory nerve lesio ned and estrogen replaced group, as
compared to the lesioned and estrogen deficient group as well as the two unlesioned
groups (Figure 7). Quantification by densitometry confi rmed this as shown in Figure 8.
Statistical analysis demonstrat ed that levels of synaptophysin in the olfactory
bulbs differed significantly among the fou r treatment groups. The TX+E2 group was
significantly higher (F~1

= 6. 13, P = 0 0056) than that in the other three groups, but there

was no significant difference betwee n TX +PL, SL+E2, and SL+PL.
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Figure 1. Western imrnunoblot showing 35 k:Da apoE protein bands two weeks postlesioning. Four groups of mice either had their olfactory nerves lesioned using Triton XI 00 (+) or exposed to saline (-) and an estrogen pellet (+) or placebo (-) implanted.
Results show an increase in the amount of apoE in mice implanted with estrogen pellets
that had olfactory nerves lesioned(+/+). The relative amounts of apoE in the other
groups remained very similar to the controls (-/-).
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Figure 2. Quantification of apoE in the olfactory bulbs of the same four treatment groups
two weeks post-lesion. The lesioned and estrogen replaced group showed significantly
higher levels of apoE as compared to the other experimental groups. There were no
significant differences in apoE levels for the other three experimental groups.
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Figure 3. Western immunoblot for GFAP of the same four treatment groups two weeks
post-lesion. Results show an increase in the two lesioned groups that is independent of
estrogen administration. There are no observable differences between the two unlesioned
groups.
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Figure 4. Quantification ofGFAP in the olfactory bulb for the same four treatment
groups two weeks post-lesion. The two lesioned groups show significantly higher
olfactory bulb levels of GFAP than the two unlesioned groups. This increase is
independent of estrogen administration. There are no observable differences between
GF AP levels in the two lesioned groups and there are no observable differences between
the GF AP levels in the two unlesioned groups.
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Figure 5. Western immunoblot for OMP for the same four experimental groups two
weeks post-lesion. OMP levels in the lesioned and estrogen deficient group are
dramatically lower than any of the other experimental groups.
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Figure 6. Quantification of OMP in the olfactory bulb for the same four experimental
groups two weeks post-lesion. OMP levels in the lesioned and estrogen deficient group
were dramatically lower than any of the other experimental groups, including the
lesioned and estrogen replaced group. However, these differences were not statistically
significant.
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Figure 7. Western immunoblot for synaptophysin levels in the olfactory bulb for the same
four experimental groups two weeks post-lesion. Synaptophysin levels were dramatically
higher in the lesioned and estrogen replaced group than in any ofthe other experimental
groups. Synaptophysin levels were lowest in the lesioned and estrogen deficient group.
There are no observable differences between the two unlesioned groups.
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Figure 8. Quantification of synaptophysin in the olfactory bulb of the same four
experimental groups two weeks post-lesion. Levels of synaptophysin in the lesioned and
estrogen replaced group were significantly higher than in any of the other experimental
groups.
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Discussion

Previous studies have shown that estrogen loss is a major risk factor for AD.
Significantly more AD patients are females than males, owing to the loss of estrogen
during menopause. Furthermore, recent studies have shown that estrogen replacement
therapy reduces the risk, delays the age of onset and slows the progression of AD
(Paganini-Hill and Henderson, 1996). Estrogen loss is not an issue for males, because
they produce endogenous estrogen throughout their lives, by converting testosterone into
estrogen in adipose tissue through the enzyme aromatase (Hadley, 1996). How estrogen
is involved in nerve repair is unclear and this study has shed light on this complex
process.
In order to test the effects of estrogen on apoE levels and nerve regeneration, the
olfactory nerve of mice was used as a moael The olfactory system provides a convenient
model for this study. This model is well suited to nerve regeneration studies since the
olfactory receptor neurons are able to regenerate. Also, the olfactory bulbs are the only
system in the CNS in which total degeneration can be experimentally induced. These
two properties make the olfactory bulbs an ideal model for this study.
Studies on the effects of lesioning and estrogen on apoE levels in the olfactory
bulb revealed that estrogen is required for upregulation of apoE levels. The levels of
apoE in the TX+E2 group were significantly higher than those in the TX+PL group. This
finding is consistent with a previous finding that showed a 1.5-fold increase in apoE
levels in the olfactory bulb following olfactory nerve lesioning in mice (Nisar, 1999). In
contrast to the lesioned group, the non-lesioned groups (SL+E2 and SL+PL) showed no
increase in apoE levels. The latter finding demonstrates that injury is necessary for

?Q

upregulation of apoE expression. Estrogen, in the absence of injury, had no significant
difference from placebo-treated group. These data suggest that estrogen increases apoE
levels in the olfactory bulb only when the olfactory nerve is injured.
Glial fibrillary acidic protein (GFAP) is a marker for astroglia (the cells which
produce apoE in the brain). Ol factory nerve lesioning dramatically increased the GFAP
levels in mice. This finding is consistent with previous findings (Poirier et al., 1991).
Interestingly, GFAP level was not influenced by the availability of estrogen, since there
is no significant difference in the GFAP expression between TX+E2 and TX+SL. Also,
estrogen administration, in the absence of injury, had no significant effects on GF AP
levels in the bulb. Mice from both SL+E2 and SL+PL had similar amounts ofGFAP in
the olfactory bulb. These data demonstrate that astroglia are either recruited or activated
at the site of injury, presumably to provide apoE and other components to facilitate nerve
repair.
Olfactory marker protein (OMP) was used as a marker to monitor actual nerve
regeneration in the olfactory bulb . Two weeks following nasal irrigation of TX the OMP
levels in the TX-E2 group was about 70% of normal levels (OMP levels in SL+PL). This
data is consistent with previous studies (Nisar, 1999). Interestingly, the OMP level is
lower in the TX-PL group as compared to the TX-E2 group. In the TX-E2 group, OMP
levels are about 40% of the non-lesioned groups two weeks after lesioning. This
indicates that regeneration is more complete in the estrogen replaced and lesioned group
of an imals, whereas, repai r is delayed in the lesioned group without estrogen. Again,
there is no difference in the non-lesioned groups where OMP level is presumably normal.
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Synaptophysin is a protein expressed in the synaptic terminals, and therefore, is
commonly used as a marker for synaptogenesis. The TX+E2 group showed higher levels
of synaptophysi n th an did any other groups. Synpatophysin levels in the TX+PL group
were significantly lower than any of the other groups. There was no significant
difference between the non-lesioned groups. These levels of synaptophysin are
presumabl y normal levels. It is not clear as to why synaptophysin levels in the TX+E2
are higher in the lesioned and estrogen replaced group than in the non-lesioned groups. It
may be because neurons produce many axons and dendrites in the early stages after nerve
repair. However, these projections and connections are pruned during the later stages of
repair process, (Purves et al., 1997).

In the absence of estrogen, the TX+PL group had

decreased synaptophysin levels. This latter result is consistent with the decreased levels
of OMP in the bulb.
Taken together these results suggest that the beneficial effects of estrogen on the
nervous system are evident only in the presence of injury. These results are consistent
with a recent study in humans. In this study, the effects of estrogen replacement therapy
(ERT) on the cognitive and olfactory abilities of healthy post-menopausal women were
investigated. It was hypothesi zed tha t women given ERT wou ld show improvement in
olfactory ability and cognition as compared to a placebo treated group. However, ERT
had no detectable effects on either cognition or on olfaction. Parallel studies in mice
subjected to long-term estrogen elevation found only transient changes in the synaptic
density of olfactory neurons (Nathan, personal communication). These findings, along
with the findings of this project, demonstrate that estrogen has no long-term effects on
the CNS of neurologically intact subjects.
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The data from this study also provides the pathway whereby estrogen facilitates
nerve repair. In the presence of estrogen, nerve injury results in an increase in the
number of astroglia at the site of damage. These glial cells produce and release apoE
(Boyles et al., 1985; Pitas et al., J987; Poirier et al., 1991 ).

This increased production of

apoE then facilitates nerve repair probably by redistributing lipids from the degenerating
nerve terminals to regenerating axons of the olfactory nerve. Enhanced regeneration of
olfactory receptor neurons then results in increased synaptogenesis as shown by the
synaptophysin data.
In conclusion, estrogen has dramatic effects on apoE levels in an injured olfactory
system. This pioneering study outlines the pathway whereby estrogen and apoE may
work in concert to bring about nerve repair. More research is needed with regard to the
interaction of estrogen and apoE and possibly other components and their functions in
nerve repair. This line of research promises to shed light on many of the unknown
disease processes at work in devastating neurodegenerative diseases, such as AD.
Uncovering how apoE isoforms affect AD and what roles estrogen play in
neuroprot ection may very well lead to means of prevention and treatment of this
devastating disease as well as other neurodegenerative diseases. It is very important that
research at the cellular and molecular level of nerve damage in the CNS is persued.
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